P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YRS OF ADJ TAMOXIF

P3 RAN DB -来曲唑 VS PLAC 主要 BR CA 完成 5 或 5 年 ADJ 他莫昔夫

• 批准号: 7378558
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.39万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378558
• 关键词: P3; RAN; DB; LETROZOLE; VS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preliminary research suggests cancer recurring may be reduced if letrozole is taken after five years of tamoxifen. The purpose of this study is to find out whether it is better to receive letrozole or no further treatment after stopping tamoxifen. The second purpose is to determine how the treatment affects the quality of life.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。初步研究表明，如果在他莫昔芬五年后服用letrozole，可能会降低癌症。这项研究的目的是找出停止他莫昔芬后更好地接受letrozole还是没有进一步的治疗。第二目的是确定治疗如何影响生活质量。